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Abstract  
 
Background: Heart failure (HF) is a complex and highly debilitating clinical syndrome. 
International guidelines identify the optimum clinical management of patients living 
with HF in primary care but translation of these into practice remains inadequate. The 
aim of this service evaluation is to measure standards of HF diagnosis and 
management, before and after, the implementation of The Greater Manchester Heart 
Failure Investigation Tool (GM-HFIT), a facilitated ‘tool kit’ designed to optimise HF 
care.  Methods: The GM-HFIT was developed as a means of assessing and improving 
care and was implemented as part of a facilitated service improvement and evaluation 
in primary care using a prospective, pre-test, post-test design. Results: Anonymised 
pre and post audit data were taken from a sample of 1130 cases entered on General 
Practice HF registers. These cases were from 2 clinical commissioning groups (39 
General Practices) in the North West of England and were analysed to compare HF 
management and treatment parameters against clinical guidelines. Implementation of 
the GM-HFIT tool kit was associated with a reduction in the number of patients 
inappropriately placed on the HF register (p<0.001), an improvement in the recording 
and documentation of pulse rate and rhythm (p=0.005) and the proportion of patients 
receiving the target dose of Angiotensin Converting Enzyme Inhibitors and Beta 
Blockers (p<0.001). There was no significant difference in the recording and 
documentation of blood pressure levels or in documented target blood pressure levels 
across the time points.  
Conclusion: The introduction of the GM-HFIT kit was associated with statistically 
significant improvements in the identification and clinical management of patients 
diagnosed with HF in primary care. 
 
Key words: Heart Failure, Primary Care, Service evaluation 
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Background  
Heart Failure (HF) is a non-communicable, life-limiting syndrome characterised by a 
constellation of unpleasant symptoms that have a negative impact upon quality of life 
[1]. HF has been described as a new ‘epidemic’ and will affect 1 in 15 people aged 65-
85 by 2020, making it a significant burden nationally and globally [2]. The HF disease 
trajectory is characterised by frequent unplanned and costly admissions to hospital [3]. 
Moreover the prognosis for people living with HF, although improved in recent years, 
is poor with approximately one third of people diagnosed with HF dying within twelve 
months [4].  
Accurate diagnosis and appropriate HF management reduces mortality and morbidity 
and the associated cost in human suffering and healthcare resources [1]. Diagnosis is 
far from straight forward and evidence suggests that diagnosis is missed in up to 70% 
of cases [6]. Little appears to have changed over the last decade in the way HF is 
diagnosed [7]. An additional complexity surrounds the evidence base, which focuses 
mostly on HF treatment for people diagnosed with HF due to Left Ventricular Systolic 
Dysfunction (LVSD) rather than HF with Preserved Ejection Fraction (HFpEF) adding 
to a lack of clarity [8].  
Natyional and international guidelines [1,5] provide evidence-based 
recommendations for pharmacological and non-pharmacological management of 
patients with HF.  However the translation of guidance from paper into practice 
remains rather patchy and patients do not always receive care that matches 
recommendations, which impacts negatively on morbidity and mortality rates [9].    
In the UK, the Quality Outcomes Framework (QOF) [11] provides a financial 
incentive to primary care providers for four indicators of care related to heart failure:  
1) Maintenance of a register of patients with heart failure;  
2) Diagnosis of heart failure confirmed by echocardiogram;  
3) Patients with LVSD being prescribed an angiotensin converting enzyme inhibitor 
(ACEI) or an angiotensin receptor blocker (ARB) if ACEI not tolerated, or 
contraindications documented; and  
4) Patients with LVSD on a beta blocker (BB), or contraindications documented.   
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Although important, these recommendations are somewhat limited (for example they 
do not incentivise up-titration of ACEI or BB to recommended doses), and their 
influence on other aspects of evidence-based care for patients with HF is unknown.   
What is known is that getting evidence into practice is difficult as behaviour change is 
required. Education alone is insufficient in promoting change as barriers and enablers 
to change exist at both organisational and individual levels [10]. Barriers to the 
implementation of best evidence in HF diagnosis and management in general practice 
include a lack of a confidence amongst health professionals around HF diagnosis and 
management compounded by a lack of awareness about current evidence; a scenario 
that appears to have altered very little over time [7]. The GM-HFIT was developed as 
a means of assessing and improving care and was implemented as part of a facilitated 
service improvement and evaluation in primary care using a prospective, pre-test, 
post-test design.  
 
Service Improvement Initiative: The development and implementation of GM-
HFIT  
 
The GM Heart Failure Investigation Tool (GM-HFIT) originated from work conducted 
through the Greater Manchester Collaborative Leadership for Applied Health 
Research and Care (GM CLAHRC) programme; a collaboration between the 
University of Manchester and NHS partners funded by the National Institute of 
Health Research designed to  improve care for patients with vascular disease.  
Improving the management of heart failure in primary care through evidence-based 
practice was identified as a priority by local NHS partners based on local and 
national data identifying high hospitalisation and re-hospitalisation rates for people 
diagnosed with HF.    
GM-HFIT is unique because unlike other tools it is facilitated by an external team 
and is both evidence based, theoretically informed and context sensitive [12] drawing 
on the elements of the Promoting Action on Research Implementation in Health 
Services (PARiHS) framework [13] . Briefly, PARiHS postulates that successful 
implementation of evidence into practice (knowledge translation or transfer) is a 
function of the dynamic interaction of three components: evidence (nature, type and 
robustness), context (what elements characterise the organisation where evidence is 
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being implemented) and facilitation, the process in which an individual, or team, 
assists others to enable implementation [13, 14]. Accordingly the development of the 
GM-HFIT was directly informed by these three components. Firstly, robust evidence 
informed the tool development including relevant guidelines [1,5], systematic reviews 
of HF disease management programmes, and local knowledge from stakeholders 
and the Greater Manchester Cardiovascular and Stroke Clinical Network.  Secondly 
a series of on-going discussions and prolonged engagement with stakeholders 
provided contextual information about the organisational culture and ideas to inform 
the nature of the facilitation process that would underpin the planned 
implementation. This included stakeholder meetings involving clinicians, managers 
and patients from primary and secondary care, a mapping exercise including 
interviews with key stakeholders across the PCT to provide detailed information 
about the environment and the perspectives of clinicians regarding problems and 
issues in HF management, available expertise, and key opinion leaders. Team 
members also sought to link directly with other ongoing HF improvement efforts to 
support collaborative working. The engagement process occurred over a 12 month 
period prior to implementation.  
Thirdly facilitation specific roles (Knowledge Transfer Associates KTA) were created 
to support a robust implementation process of evidence into practice. KTA’s received 
specific training to equip them with the necessary knowledge and skills to promote 
effective organisational change and knowledge transfer. Heart failure specialist 
nurses (HFSN) were seconded to work alongside the KTA’s to provide the necessary 
clinical expertise. The facilitation process was supported by four factors; 
• The provision of a service that benefited practices: case-finding and HF 
register verification provided an economic incentive through QOF.  
• The acceptance of HFSNs as a ‘link’ across organisational boundaries.  
• Formal and informal education was provided to participating CCGs delivered 
by team members as required and tailored to learning need.  
• The provision of support to facilitate changes to practice.   
 
GM-HFIT features 
The GM-HFIT is an approach characterised by a facilitated audit process. GM-HFIT 
consists of three components; case-finding, register verification and audit. Figure 1 
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shows the key steps in each step of the implementation cycle. In brief, case finding 
was conducted using 15 discrete searches (available from corresponding author) in 
which ‘Read Codes’ (a coded system of clinical terms used in the NHS since 1985) for 
medications, echocardiography and associated conditions were entered into the 
general practice computer system to identify cases.  The clinical audit criteria 
consisted of 21 indicators reflected in the relevant guidelines [1,5]. Composite scores 
were calculated according to the proportion of patients in the practice meeting each 
standard, and summed to a total of 80 possible points. Scores on the audit were based 
on data documented in the medical record, and included the patients on the HF 
register at the time of audit. The aim was to measure standards of HF diagnosis and 
management before and after the implementation of the GM-HFIT service 
improvement initiative.    
 
 
 
 
Methods 
Study Design 
A service improvement and evaluation with clinical audit designed to measure 
standards of HF diagnosis and management before and after the implementation of 
GM-FIT ‘tool kit’ in primary care settings in the North West of England. 
 
Fig 1. Steps in the implementation of the Greater Manchester Heart Failure 
Investigation Tool 
 
INSERT FIGURE 1 
 
Service Improvement Setting  
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England has 211 Clinical Commissioning Groups (CCGs) which are clinician led 
organisations, made up of General Practitioner Practices, who work with local 
authorities to plan and commission most community, mental health services and 
hospital care based on the needs of local populations. GM-HFIT was initially 
developed, piloted, refined, and implemented in one large primary care trust (PCT) 
which had identified cardiovascular health as a priority for improvement in Greater 
Manchester 2009 - 2011.  Primary care practices were recruited from 3 different 
areas of the PCT, to reflect the diversity of services in these areas (e.g. community 
HFSN, local enhanced services [LES] for HF) and referral relationships with 3 acute 
care trusts across the PCT.  Practices were recruited from the stakeholder groups, 
through clinical meetings, and recommendation and introduction by clinicians.  Two 
GPs with a special interest (GPwSI) in heart failure assisted in recruiting practices 
and supporting the work.  The initial piloting of GM-HFIT was done with six LES 
practices, which were not re-audited.  In this study we report findings from a follow 
on audit and evaluation conducted from January 2012 to December 2013 with data 
collected from one complete CCG comprising, 27 practices, and one locality of 
another CCG comprising 12 practices in which the GM-HFIT was implemented.   
Procedure  
Recruited practices provided access to the practice information system and a place 
for the GM-HFIT team (One KTA and HFSN) to work collaboratively on case finding, 
audit, review and interpret medical records, discuss and make recommendations for 
patient management, and serve as a bridge between primary care and specialist 
services. The initial case-finding, register validation, and audit took between 2-4 days 
depending on the size of the practice. Medical records of patients identified in case 
finding and those patients on the HF register were reviewed by the HFSN for 
diagnostic tests and verification of HF diagnoses. Patients on the HF register without 
a verified HF diagnosis of HF were referred to the GP for further evaluation or requests 
made to follow up on test results. Case-specific recommendations and an action plan 
were developed for the practice based on the findings. Detailed feedback was given 
in conjunction with an individualised development pack.  Practices had access to 
educational sessions delivered by local HFSNs and support by telephone. Practices 
were expected to add or remove patients from the HF register as recommended, 
arrange tests and follow-up as appropriate. Recommendations were made for the 
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management of individual patients along with suggestions for the improvement of 
systems used to coordinate ongoing patient review and management. Re-audit 
occurred at 6-12 months 6 - 9 months following the initial audit.  
 
Ethical approval  
Because this was an audit and service improvement programme, no ethical 
permission was needed according to advice from Ethics committees consulted by 
GM CLAHRC.  Each practice consented to take part in the GM-HFIT programme, 
which included accessing records for the audit. Patient identifying data were only 
seen by NHS staff, and only anonymous patient data used for analysis.   
 
Data Analysis 
During the GM-HFIT process, anonymous patient data were entered into the GM-
HFIT template and collected to an MS Excel file for the purpose of the audit, and 
then exported to a SPSS 20.0 database. The analysis took place in two phases to 
generate descriptive and inferential statistics. For the purpose of the analysis cases, 
which represented individual patients, were grouped into one of three discreet 
categories. These were; ‘case finding’ (Cases identified as appropriate for inclusion 
on the HF register during the audit period who were not currently included), ‘new 
cases’ (Cases identified at T2 as appropriate for inclusion on register but with no 
previous evidence of HF at T1 e.g. people who moved into the locality with a 
diagnosis of HF and registered at the practice or those who developed HF during the 
audit period), ‘existing cases’ (Cases not in the other groupings with data identified at 
both T1 and T2). 
 
 
Analysis 1. The aim of analysis 1 was to determine whether cases that had been 
actively added to the register, as a result of the audit, differed from those identified at 
the beginning of the audit, by demographic characteristics or disease history. Records 
from ‘new cases’ and ‘case finding’ were extracted for comparison with ‘existing 
cases’. New cases and case findings were compared to existing patients’ data at T2. 
Demographics and disease characteristics across the three groups were compared 
using chi squared tests.  
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Analysis 2. The aim of Analysis 2 was to evaluate changes in the management and 
care of patients with HF between T1 and T2 according to key indicators that reflect 
best practice recommendations in clinical guidelines. All patients who had records at 
both Time 1 and Time 2 were extracted to form a matched dataset. Demographics 
and disease characteristics were compared using McNemar’s test for matched pairs.  
 
Results 
A total of 1953 records were extracted, of which 33 (1.5%) were excluded for missing 
data across the majority of the variables (5 case findings, 14 new cases and 11 
existing cases). Five patients (existing cases) deceased between Time 1 and 2 and 
their records were excluded from the analysis. The proportion of missing data was 
highest for new cases, at 6.4% of records, compared to 1% each for existing cases 
and case findings. The final analysed sample comprised 1130 existing patients (with 
records at Time 1 and Time 2 available for matched analysis), 205 new cases and 
583 case findings (Table 1).  
Analysis 1: At the second audit, 63% of the patients were male, and the majority of 
patients were aged between 70 and 90 years (59%). The median age of existing 
patients was 75 years, while new cases’ median age was 76 years. Case findings 
had a median age of 73 years.  Case findings were more likely to be male (71%) 
than new cases (59%) or existing cases (60%, P<0.001), and were younger (35% 
aged less than 50 years, compared to 22% of new cases and 30% of existing cases, 
P<0.001). Most patients identified through the case finding exercise were 
appropriately on the register (98%), significantly more so than new cases (80%) or 
existing cases (83%:  P<0.001). The vast majority of case findings were diagnosed 
with LVSD (93%. In contrast, only 67% of new cases and 73% of existing cases had 
an LVSD diagnosis (P<0.001).  Of those with LVSD, case findings were healthier in 
general than new cases or existing cases, with 40% having ‘normal’ or ‘mild’ ejection 
fractions (compared with only 27% of new cases and 32% of existing cases, 
P<0.001). The proportion of patients with haemodynamic parameters recorded at the 
recommended level (Blood pressure ≤130/80 hg/ml and pulse rate ≤70 bpm) did not 
differ between groups (P>0.05). Case findings were slightly more likely to have a 
regular rhythm. New cases were more likely to have had their pulse and rhythm 
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taken, but of those with LVSD, they were the least likely to have had an 
echocardiogram. There was no difference between the groups in the likelihood of the 
blood pressure being recorded.  
Insert Table 1 here please 
Analysis 2: In order to measure any improvement in compliance with best practice 
guidelines between the two time periods, analysis of cases that were on the register 
at both time points was carried out.  Over the audit period, the proportion of patients 
who were appropriately on the register improved from 78.6% at Time 1 to 82.9%, 
while the proportion of patients who needed further investigation decreased from 
15.5% to 10.2% (P<0.001). However, the proportion inappropriately on the register 
increased slightly from 5.9% to 6.9%. Table 2 shows that the proportion of patients 
having had an echocardiogram and their aetiology established improved between 
the periods, as did the proportion with pulse and rhythm recorded (blood pressure 
recording remained relatively high, at 95% in both periods).  
Insert Table 2 here please 
There was no significant improvement in the proportion of patients that were 
prescribed ACE inhibitors or BBs, but of those who were prescribed these 
medications, the proportion who were taking the appropriate dose, or were up-
titrating, did improve markedly from 76% to 89% for ACE inhibitors, and 75% to 88% 
for BBs (both P<0.001). Audit indicators differed little between the two time periods, 
with around 62% having achieved target blood pressure (≤130/80 hg/ml). 
Discussion 
GM-HFIT was based on the best available evidence, used extensive stakeholder 
consultation to understand the context of care and had a robust method of facilitation 
involving formal and informal interactive education and support, audit, feedback and 
reminders. Analysis of the process revealed a complex interplay between context 
(from national initiatives to individual clinician and practice) and facilitation [15].  
Contextual tensions including pressures on the service, reward for some (eg QOF 
indicators) but not all activities, and organisational issues needed to be negotiated 
between practice and GM-HFIT team. The extent to which practices engaged with 
the process varied based on motivation for the project (whether internal or externally 
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imposed), up-skilling staff and clinician willingness to take responsibility for making 
changes.  HFSN were seen as being clinically credible and were able to work with 
clinicians to particularise evidence for individual patients [15].   
The typical profile of the 1130 audited cases of patients drawn from 39 GP practices 
in Greater Manchester was of a male, aged 70-90 years of age with a diagnosis of 
LVSD and Ejection fraction of 45-54%. This profile bears some similarities to that of 
the sample reported in the National HF Audit [16]; which suggests there is some 
support for the generalizability of the audit findings. However this demographic profile 
is more typical of patients seen by a cardiologist rather than in a general practice 
setting, where a typical patient tends to be an older female diagnosed with 
hypertension [17]. Overall 95% of cases were appropriately on the HF register or 
awaiting investigation leaving 5% inappropriately included. Less than 5% of the 
audited cases had not had an echocardiogram. The case finding exercise tended to 
identify missed patient cases who were male, younger on average, with a diagnosis 
of LVSD (rather than being inappropriately on the register or requiring further 
investigation) and a higher ejection fraction than other new or existing cases. It is 
unclear why this occurred. One explanation may be that patients with a higher ejection 
fraction may report fewer symptoms on presentation to their General Practitioner 
thereby reducing their likelihood of being included on the HF register. Studies have 
shown that more than 50% of patients diagnosed with LVSD show no signs or 
symptoms of HF [18,19].  
 
Overall about 95% of patient cases had their blood pressure recorded, and 64% their 
pulse recorded, but this did not lead to a high level of patient cases showing 
parameters that aligned with recommendations. A meta-analysis demonstrated the 
importance of heart rate reduction and survival in patients diagnosed with chronic 
heart failure; an 18% reduction in death as associated with each heart rate reduction 
of 5bpm [20]. These findings suggest that interventions to support guidelines informed 
HF care are necessary. 
 
Considering the findings from the audit of the 1130 matched cases, conducted before 
and after the introduction of GMHF-IT, findings showed that the implementation of the 
GM-HFIT was associated with an improvement in several clinical audit indicators of 
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gold standard HF diagnosis and management. Patients were more likely to have had 
an echocardiogram and have their aetiology established, were more likely to be 
prescribed appropriate disease modifying treatments at target doses, or be in the 
process of up-titration. Before the service improvement intervention, patients were just 
as likely to be appropriately prescribed disease modifying treatments but were less 
likely to be on (or working towards) the appropriate target dose. Interestingly the 
proportion of patients, eligible for, and appropriately prescribed disease modifying 
treatments (ACEI/ARB or BB), was impressively high (>90%) compared to National 
Audit Data (80-85%). These data appear, however,  to be closer to those reported in 
Registry data collated across Europe [21].  
 
This suggests either that practices were already delivering gold standard level HF 
management in the prescription rates of disease modifying treatments, or that the 
planning and facilitation phase of the GM-HFIT, which took over a year elicited change. 
This could potentially minimise the significance of any association between the service 
improvement intervention and changes in audit indicators recorded at the two time 
points.  
 
Interestingly the improvements in the prescription rates was not reflected in significant 
changes in physiological parameters, although this would not necessarily indicate a 
lack of clinical benefit. An area for improvement concerned the recording and 
documentation of pulse rate and rhythm, as only 68% and 49% respectively had pulse 
and rhythm documented after the audit. This improved during the audit period but was 
still not at an optimum level. Heart rate and rhythm control is particularly important in 
this patient population given their predisposition to arrhythmias such as atrial 
fibrillation. Moreover inadequate heart rate control in patients diagnosed with chronic 
HF leads to poorer clinical outcomes and is relatively common, despite treatment with 
beta-blocker therapy [22]. 
 
The provision of lifestyle advice, although improved, remained at a low level and may 
be due to a health professional’s lack of confidence, or pressure of time. Around 70% 
of patients post audit had not been given lifestyle advice according to the records. This 
may be explained by a lack of record keeping. However other studies have reported 
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that patients with HF often do not receive self-management advice, and even if they 
do, they do not remember it [23].   
 
The study has a number of limitations which could have influenced findings and 
therefore warrant attention. Although changes in practice were seen, the short time 
between initial audit and re-audit meant that practices reported being in the midst of 
implementing recommended changes and still evaluating patients who needed further 
investigation. The practices involved in this initial work were willing to participate, so 
represent a self-selected group interested in improving management of patients with 
HF and the sustainability of improvements in these practices is not known. That said 
the study presents a novel service improvement that is theoretically based and based 
in a ‘real’ life setting. While there are improvements in HF care, there remains a need 
to improve the accuracy of HF registers, identification and management of patients in 
primary care. Patients who are not allocated the correct code corresponding with a 
diagnosis of HF are unlikely to receive optimum care.  
 
A greater emphasis on the provision of self-management support and advice for 
patients and their families is warranted. The individualised education provided to the 
clinical team of participating sites was an important part of the implementation process 
and enabled an ongoing improvement process. The collaborations that were 
developed between HFSNs and practices made it easy for informal consultations and 
advice seeking about particular patients to occur. In conclusion modest but significant 
improvements can occur with appropriate support using approaches such as the GM-
HFiT.  
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Fig 1. Steps in the implementation of the Greater Manchester Heart Failure 
Investigation Tool 
 
 
 
  
Months 1-6 
Audit time 1 (T1): 
-Register Verification
- Case Finding
-Heart Failure Management 
Months 1-6 
Education sessions with 
practice teams
Months 2-7
Feedback of audit data 
to practice teams
Months  6-12
Re-Audit time 2 (T2)
Month 12
Feedback of audit data 
to practice team
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Table 1: Participant characteristics 
 
All cases 
Total  
(1918) 
Case finding  
 (n=583) 
New cases 
 (n=205) 
Existing cases  
 (n=1130) 
Chi 
square 
Gender     Chi=23.9 
Df=2 
P<0.001 Male 
1213 
(63.3%) 416 (71.4%) 120 (58.6%) 677 (60%) 
Female 705 (36.8%) 167 (28.7%) 85 (41.5%) 453 (40.1%) 
Age group 
(years)      
< 
50 92 (4.8%) 29 (5%) 18 (8.8%) 45 (4%) Chi=26.8 
Df=6 
P<0.001 
50-<70 584 (30.5%) 202 (34.7%) 45 (22%) 337 (29.9%) 
70-<90 1131 (59%) 333 (57.2%) 127 (62%) 671 (59.4%) 
90+ 111 (5.8%) 19 (3.3%) 15 (7.4%) 77 (6.9%) 
Appropriately on Register     
Appropriate 
1675 
(87.4%) 574 (98.5%) 164 (80%) 937 (83%) Chi=96.7 
DF=4 
P<0.001 
Inappropriate 94 (5%) 3 (0.6%) 13 (6.4%) 78 (7%) 
Needs further 
investigation 149 (7.8%) 6 (1.1%) 28 (13.7%) 115 (10.2%) 
Diagnosis      
LVSD 
1508 
(78.7%) 540 (92.7%) 137 (66.9%) 831 (73.6%) 
Chi=125 
DF=8 
P=<0.001 
HF with 
Preserved  
Ejection 
Fraction  109 (5.7%) 29 (5%) 16 (7.9%) 64 (5.7%) 
Right Sided 29 (1.6%) 4 (0.7%) 6 (3%) 19 (1.7%) 
Other 33 (1.8%) 1 (0.2%) 8 (4%) 24 (2.2%) 
NA* 239 (12.5%) 9 (1.6%) 38 (18.6%) 192 (17%) 
Echo taken     Chi=40.0 
DF=2 
P<0.001 Yes 
1835 
(95.7%) 580 (99.5%) 184 (89.8%) 1071 (94.8%) 
No 83 (4.4%) 3 (0.6%) 21 (10.3%) 59 (5.3%) 
Blood pressure 
recorded     Chi=5.64 
DF=2 
P=0.060 yes 
1813 
(94.6%) 541 (92.8%) 198 (96.6%) 1074 (95.1%) 
no 105 (5.5%) 42 (7.3%) 7 (3.5%) 56 (5%) 
Pulse recorded     Chi=38.0 
DF=2 
P<0.001 yes 
1215 
(63.4%) 329 (56.5%) 165 (80.5%) 721 (63.9%) 
no 703 (36.7%) 254 (43.6%) 40 (19.6%) 409 (36.2%) 
Rhythm recorded     Chi=41.2 
DF=2 yes 925 (48.3%) 236 (40.5%) 136 (66.4%) 553 (49%) 
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no 993 (51.8%) 347 (59.6%) 69 (33.7%) 577 (51.1%) P<0.001 
      
Blood pressure      Chi=0.780 
DF=2 
P=0.677 
BP > 130/80 682 (37.7%) 210 (38.9%) 70 (35.4%) 402 (37.5%) 
BP =< 130/80 
1131 
(62.4%) 331 (61.2%) 128 (64.7%) 672 (62.6%) 
Pulse rate      Chi=3.57 
DF=2 
P=0.168 
Rate => 70 608 (50.1%) 150 (45.6%) 85 (51.6%) 373 (51.8%) 
Rate < 70 607 (50%) 179 (54.5%) 80 (48.5%) 348 (48.3%) 
Rhythm      Chi=23.2 
DF=2 
P<0.001 
Regular 602 (65.1%) 184 (78%) 84 (61.8%) 334 (60.4%) 
Irregular 323 (35%) 52 (22.1%) 52 (38.3%) 219 (39.7%) 
Of those with 
LVSD:      
Ejection Fraction recorded    Chi=9.72 
DF=2 
P=0.008 Yes 
1486 
(98.6%) 538 (99.7%) 132 (96.4%) 816 (98.2%) 
No 22 (1.5%) 2 (0.4%) 5 (3.7%) 15 (1.9%) 
Ejection Fraction     
≥55% 
(Normal) 6 (0.5%) 1 (0.2%) 0 (0%) 5 (0.7%) 
Chi=34.7 
DF=6 
P<0.001 
45 - 54% 
(Mild) 503 (33.9%) 214 (39.8%) 36 (27.3%) 253 (31.1%) 
36 - 44% 
(Moderate) 485 (32.7%) 193 (35.9%) 43 (32.6%) 249 (30.6%) 
≤35% 
(Severe) 492 (33.2%) 130 (24.2%) 53 (40.2%) 309 (37.9%) 
LVSD= Left Ventricular Systolic Dysfunction. *Not applicable owing to: No 
HF/requires further investigation/iappropriately on register. 
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Table 2: Clinical audit indicators identified at Time 1 and Time 2 and rate of 
compliance with best practice recommendations. 
 n   Exact p 
  Time 1  Time 2   
Clinical audit indicators  
 Compliant 
(%) 
 Compliant 
(%)  
Echocardiogram recorded 1130 92.2 94.8 <0.001 
Aetiology established 1130 86.5 92.0 <0.001 
Blood Pressure recorded 1130 94.6 95.0 0.668 
Pulse recorded 1130 57.7 68.3 <0.001 
Rhythm recorded 1130 44.0 48.9 0.003 
Prescribed ACE I 792a 91.2 90.3 0.382 
Prescribed BB 792a 84.5 85.6 0.38 
ACE target dose/or 
uptitrating in progress 636b 76.1 88.7 <0.001 
BB target dose /or up 
titrating 534 b 75.3 87.6 <0.001 
Given self-care advice 1130 22.4 31.6 <0.001 
BP ≤130/80 1028 c 61.0 63.0 0.257 
Pulse rate ≤70 524 c 46.2 51.1 0.045 
Rhythm regular 348c 57.5 58.9 0.615 
McNemar exact P values (binomial distribution) 
a Of those with LVSD, the proportion either taking ACE I or BB or contraindicated 
b Of those taking ACE I or BB, the proportion either uptitrating or on target dose 
c Of those with BP/Pulse/Rhythm recorded at both T1 and T2 
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